Corient Private Wealth LP Acquires Shares of 318,673 ADMA Biologics Inc $ADMA

Corient Private Wealth LP bought a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 318,673 shares of the biotechnology company’s stock, valued at approximately $2,667,000.

Several other hedge funds also recently made changes to their positions in the business. Summit Securities Group LLC acquired a new stake in shares of ADMA Biologics in the fourth quarter valued at approximately $29,000. Western Wealth Management LLC bought a new position in ADMA Biologics during the 1st quarter worth $31,000. iSAM Funds UK Ltd bought a new position in ADMA Biologics during the 3rd quarter worth $34,000. Morse Asset Management Inc acquired a new position in ADMA Biologics in the 4th quarter valued at $44,000. Finally, EverSource Wealth Advisors LLC lifted its position in shares of ADMA Biologics by 385.8% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,745 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 2,180 shares during the period. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Trading Down 0.6%

Shares of ADMA stock opened at $9.33 on Wednesday. ADMA Biologics Inc has a fifty-two week low of $7.21 and a fifty-two week high of $20.46. The stock’s fifty day moving average price is $9.10 and its two-hundred day moving average price is $10.40. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.81 and a current ratio of 6.97. The company has a market cap of $2.09 billion, a PE ratio of 13.33 and a beta of 0.78.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 EPS for the quarter, hitting analysts’ consensus estimates of $0.16. The company had revenue of $124.39 million during the quarter, compared to analysts’ expectations of $125.34 million. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%.ADMA Biologics’s revenue was up 2.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.14 EPS. Equities analysts predict that ADMA Biologics Inc will post 0.78 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on ADMA shares. Raymond James Financial started coverage on ADMA Biologics in a research report on Wednesday, June 10th. They issued an “outperform” rating and a $21.00 price target on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research report on Thursday, June 18th. Canaccord Genuity Group reduced their price objective on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Mizuho decreased their target price on shares of ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a report on Wednesday, July 15th. Finally, Zacks Research lowered shares of ADMA Biologics from a “hold” rating to a “strong sell” rating in a report on Tuesday, August 4th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, ADMA Biologics presently has a consensus rating of “Hold” and an average price target of $18.67.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.